David Drewry

David Drewry

SGC UNC

Drewry

David Drewry

(919) 962-5349

Biography

David Drewry is a renowned leader in the medicinal chemistry of protein kinases and is one of the principal architects of the research strategy at the SGC-UNC to build an open and collaborative research network to promote target discovery. He previously enjoyed more than 24 years as a medicinal chemist with GlaxoSmithKline and legacy companies, where he led teams working across the preclinical spectrum of drug discovery. His research interests include the art and science of medicinal chemistry, kinase inhibitor design, utilization of annotated sets of kinase inhibitors to build understanding of signaling networks and precompetitive chemical biology to facilitate target identification. After earning a Bachelor’s of Science degree, cum laude, in chemistry from Yale University, Drewry earned his doctorate at the University of California, Berkeley in the laboratory of Paul Bartlett, working on the design, synthesis and mechanistic studies of zinc protease inhibitors. Drewry is currently the head of chemistry at Meryx Pharmaceuticals, a biotech startup focused on small-molecule inhibitors of Mer kinase that was a spinoff from the UNC Eshelman School of Pharmacy. Drewry enjoys running, reading and relaxing with his family at local restaurants, the movie theater or in the kitchen playing board games.

2017

Progress towards a public chemogenomic set for protein kinases and a call for contributions.

Drewry DH, Wells CI, Andrews DM, Angell R, Al-Ali H, Axtman AD, Capuzzi SJ, Elkins JM, Ettmayer P, Frederiksen M, Gileadi O, Gray N, Hooper A, Knapp S, Laufer S, Luecking U, Michaelides M, Müller S, Muratov E, Denny RA, Saikatendu KS, Treiber DK, Zuercher WJ, Willson TM

PLoS ONE. 2017-8-3 . 12(8):e0181585 .doi: 10.1371/journal.pone.0181585

PMID: 28767711

2016

EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen.

Scheipl S, Barnard M, Cottone L, Jorgensen M, Drewry DH, Zuercher WJ, Turlais F, Ye H, Leite AP, Smith JA, Leithner A, Möller P, Brüderlein S, Guppy N, Amary F, Tirabosco R, Strauss SJ, Pillay N, Flanagan AM

J. Pathol.. 2016-4-23 . 239(3):320-34 .doi: 10.1002/path.4729

PMID: 27102572

2015

Comprehensive characterization of the Published Kinase Inhibitor Set.

Elkins JM, Fedele V, Szklarz M, Abdul Azeez KR, Salah E, Mikolajczyk J, Romanov S, Sepetov N, Huang XP, Roth BL, Al Haj Zen A, Fourches D, Muratov E, Tropsha A, Morris J, Teicher BA, Kunkel M, Polley E, Lackey KE, Atkinson FL, Overington JP, Bamborough P, Müller S, Price DJ, Willson TM, Drewry DH, Knapp S, Zuercher WJ

Nat. Biotechnol.. 2015-10-26 . .doi: 10.1038/nbt.3374

PMID: 26501955

Discovery and characterization of GSK2801, a selective chemical probe for the bromodomains BAZ2A and BAZ2B.

Chen P, Chaikuad A, Bamborough P, Bantscheff M, Bountra C, Chung CW, Fedorov O, Grandi P, Jung D, Lesniak R, Lindon M, Müller S, Philpott M, Prinjha RK, Rogers CM, Selenski C, Tallant C, Werner T, Willson TM, Knapp S, Drewry DH

J. Med. Chem.. 2015-3-23 . .doi: 10.1021/acs.jmedchem.5b00209

PMID: 25799074

2012

A public-private partnership to unlock the untargeted kinome.

Knapp S, Arruda P, Blagg J, Burley S, Drewry DH, Edwards A, Fabbro D, Gillespie P, Gray NS, Kuster B, Lackey KE, Mazzafera P, Tomkinson NC, Willson TM, Workman P, Zuercher WJ

Nat. Chem. Biol.. 2012-12-15 . 9(1):3-6 .doi: 10.1038/nchembio.1113

PMID: 23238671